Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 103

Sort by

Sort Order Select

Journal Articles

Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset

Maximilian Stahl, Jan Philipp Bewersdorf, Rahul Vedula, Yiwen Liu, H. Moses Murdock, Harrison Tsai, Evan Chen, Benjamin Rolles, Nikolai Podoltsev, Lourdes Mendez, Luca Lanino, Alain Mina, Luis E. Aguirre, Mikkael Sekeres, Lionel Ades, R. Coleman Lindsley, Amer Zeidan

Blood (2025) 146 (Supplement 1): 5651.

https://doi.org/10.1182/blood-2025-5651

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

Archana Sasi, Victor Kovac, Yiwen Liu, Jessica Little, Ann Woolley, Harrison Tsai, Vincent Ho, Shai Shimony, Eric Winer, Richard Stone, Daniel Deangelo, Marlise Luskin, Lindsey Baden, R. Coleman Lindsley, Rahul Vedula

Blood (2025) 146 (Supplement 1): 5180.

https://doi.org/10.1182/blood-2025-5180

Published: 2025

Journal Articles

Early TCR diversity and recipient stem-cell persistence predict relapse and reveal therapeutic targets after allogeneic transplantation

Blood (2025) 146 (Supplement 1): 6065.

https://doi.org/10.1182/blood-2025-6065

Published: 2025

Journal Articles

Exposure to agent orange and risk of myelodysplastic syndromes

Mikkael Sekeres, Amy DeZern, Michael Otterstatter, Eric Padron, Tareq Al Baghdadi, James Foran, Rami Komrokji, Gregory Abel, Wael Saber, Steven Gore, Cecilia Lee, Rafael Bejar, Jijun Liu, Joachim Deeg, Seth Sherman, R. Coleman Lindsley, Nancy DiFronzo, Matthew Walter, Nancy Gillis

Blood (2025) 146 (Supplement 1): 5626.

https://doi.org/10.1182/blood-2025-5626

Published: 2025

Journal Articles

Error-corrected sequencing to quantify clonal hematopoiesis in breast cancer survivors treated with metformin in a randomized, placebo controlled, prospective clinical trial

Zhan Rong, Soo Park, Laura Tennis, Timothy Luger, Sheri Hartman, Christopher Gibson, Dorothy Sears, R. Coleman Lindsley, Rafael Bejar

Blood (2025) 146 (Supplement 1): 4954.

https://doi.org/10.1182/blood-2025-4954

Published: 2025

Journal Articles

A continuum of inherited telomere dysfunction links TERT rare variants to age-related diseases

Blood (2025) 146 (Supplement 1): 749.

https://doi.org/10.1182/blood-2025-749

Published: 2025

Journal Articles

Longer telomeres in donors aged ≥35 years reduce graft failure and non-relapse mortality after allogeneic HCT

Nico Gagelmann, Kyle Hebert, Thomas McGovern, Gabrielle Schmidt, Valerie Stewart, Donna Neuberg, Stephen Spellman, Jeffery Auletta, Steven Devine, Robert Soiffer, Immaculata De Vivo, Christopher Reilly, R. Coleman Lindsley

Blood (2025) 146 (Supplement 1): 373.

https://doi.org/10.1182/blood-2025-373

Published: 2025

Journal Articles

Sickle cell disease is associated with early-onset clonal hematopoiesis involving DNA damage response pathway mutations

Blood (2025) 146 (Supplement 1): 8.

https://doi.org/10.1182/blood-2025-8

Published: 2025

Journal Articles

Prevalence and significance of cytoses in clonal hematpoiesis

Virginia Volpe, Keishla Arce-Ruiz, Yating Wang, Caitlyn Vlasschaert, Md Mesbah Uddin, Pradeep Natarajan, Daniel Deangelo, Alexander Bick, Marlise Luskin, R. Coleman Lindsley, Shai Shimony, Lachelle Weeks

Blood (2025) 146 (Supplement 1): 1387.

https://doi.org/10.1182/blood-2025-1387

Published: 2025

Journal Articles

A pre-NGS screening strategy to identify populations with high-risk clonal hematopoiesis

Riya Nandi, Caitlyn Vlasschaert, Md Mesbah Uddin, Pradeep Natarajan, Daniel Deangelo, Marlise Luskin, R. Coleman Lindsley, Alexander Bick, Shai Shimony, Lachelle Weeks

Blood (2025) 146 (Supplement 1): 1386.

https://doi.org/10.1182/blood-2025-1386

Published: 2025

Journal Articles

Ven+FluBu2 with ptcy/tac/MMF RIC transplant followed by venetoclax/azacitidine maintenance for high-risk MDS/AML

H. Moses Murdock, Kyle Hebert, Jennifer Brock, Elise Auriemma, Felicia Lim, Jeremy Ryan, Mahasweta Gooptu, Roman Shapiro, Corey Cutler, Amar Kelkar, Vincent Ho, Denbaa Bat-Erdene, Anthony Letai, Jerome Ritz, R. Coleman Lindsley, Joseph Antin, Robert Soiffer, Jacqueline Garcia

Blood (2025) 146 (Supplement 1): 4206.

https://doi.org/10.1182/blood-2025-4206

Published: 2025

Journal Articles

Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia

Rahul Vedula, Hannah Karp, Danielle Morrow, Andrew Gehrke, Yiwen Liu, Ellen Weisberg, Carter Lombardi, Rebecca Leonard, Ilene Galinsky, Jacqueline Garcia, Marlise Luskin, Maximilian Stahl, Martha Wadleigh, Eric Winer, Daniel Deangelo, James Griffin, Richard Stone, R. Coleman Lindsley

Blood (2025) 146 (Supplement 1): 3265.

https://doi.org/10.1182/blood-2025-3265

Published: 2025

Journal Articles

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Sara K. Silbert, Alexander W. Rankin, Chloe N. Hoang, Alexandra Semchenkova, Regina M. Myers, Elena Zerkalenkova, Hao-Wei Wang, Alexandra E. Kovach, Constance M. Yuan, Dana Delgado Colon, Loïc Vasseur, Alex Bataller, Samuel John, Kaylyn Utley Lyons, Barbara Friedes, Anna Alonso-Saladrigues, Hisham Abdel-Azim, Estelle Balducci, Ahmed Assim Aljudi, Marie Balsat, D. Nathan Biery, Aghiad Chamdin, Bill H. Chang, Raymund S. Cuevo, Barbara De Moerloose, David S. Dickens, Ulrich Duffner, Nicolas Duployez, Firas El Chaer, Michelle Ann Elliott, Gabriele Escherich, Sneha Fernandes, Mandi R. Fitzjohn, Zhubin Gahvari, Stephan A. Grupp, Rui Rochelle He, Cynthia Harrison, Christopher B. Hergott, Emily M. Hsieh, Annette S. Kim, Dennis J. Kuo, Daniel P. Larson, Benjamin J. Lee, Thibaut Leguay, R. Coleman Lindsley, Abhishek A. Mangaonkar, Kerstin Mezger, Holly L. Pacenta, Jing Pan, Marlie Provost, Latika Puri, Sunil S. Raikar, Armando Martinez, Isabella Bristol, Kyle Murphy, Lauren Reiman, Michele Redell, Kelly Reed, Gabrielle Roth-Guepin, Jeremy Rubinstein, Süreyya Savaşan, Kristian Schafernak, Alexandra Stevens, Aimee Talleur, Naomi Torres Carapia, Jacques Vargaftig, Anant Vatsayan, Matthias Wölfl, Liping Zhao, Susana Rives, Vanessa A. Fabrizio, Koji Sasaki, Ibrahim Aldoss, Nicolas Boissel, Susan R. Rheingold, Kara L. Davis, Sara Ghorashian, Elad Jacoby, Alexander Popov, Adam J. Lamble, Nirali N. Shah

Blood (2025) 146 (4): 437–455.

https://doi.org/10.1182/blood.2024026655

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Blood (2025) 145 (18): 1987–2001.

https://doi.org/10.1182/blood.2024025131

Published: 2025

Includes: Supplemental data

Journal Articles

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 4597.

https://doi.org/10.1182/blood-2024-206034

Published: 2024

Journal Articles

Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)

Blood (2024) 144 (Supplement 1): 1831.

https://doi.org/10.1182/blood-2024-201613

Published: 2024

Journal Articles

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2950.

https://doi.org/10.1182/blood-2024-194922

Published: 2024

Journal Articles

Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group

Shai O. Shimony, Yating Wang, Angel Cronin, Thomas P Walsh, Anne Charles, Natalie Slopen, Maximilian Stahl, Rebecca P. Bystrom, Marlise R. Luskin, Gregory Abel, Daniel J. DeAngelo, Richard M Stone, R. Coleman Lindsley, Andrew Hantel

Blood (2024) 144 (Supplement 1): 5171.

https://doi.org/10.1182/blood-2024-203644

Published: 2024

Journal Articles

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Shai O. Shimony, Heardley Murdock, Julia Keating, Christopher R. Reilly, Harrison K. Tsai, Christopher J. Gibson, Stefan Faderl, Tony Wagner, Nalina Dronamraju, Tara L. Lin, Ellen K. Ritchie, Thomas Prebet, Jorge E. Cortes, Geoffrey L. Uy, Jeffrey E Lancet, Donna S. Neuberg, Richard M. Stone, R. Coleman Lindsley

Blood (2024) 144 (Supplement 1): 60.

https://doi.org/10.1182/blood-2024-200413

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

Early TCR diversity and recipient stem-cell persistence predict relapse and reveal therapeutic targets after allogeneic transplantation

Exposure to agent orange and risk of myelodysplastic syndromes

Error-corrected sequencing to quantify clonal hematopoiesis in breast cancer survivors treated with metformin in a randomized, placebo controlled, prospective clinical trial

A continuum of inherited telomere dysfunction links TERT rare variants to age-related diseases

Longer telomeres in donors aged ≥35 years reduce graft failure and non-relapse mortality after allogeneic HCT

Sickle cell disease is associated with early-onset clonal hematopoiesis involving DNA damage response pathway mutations

Prevalence and significance of cytoses in clonal hematpoiesis

A pre-NGS screening strategy to identify populations with high-risk clonal hematopoiesis

Ven+FluBu2 with ptcy/tac/MMF RIC transplant followed by venetoclax/azacitidine maintenance for high-risk MDS/AML

Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only